AstraZeneca's Brennan Suggests Exclusivity As Carrot For Finding Drugs To Treat Neglected Diseases
This article was originally published in PharmAsia News
Executive Summary
The opportunity to obtain extended exclusivity would be an effective method to spur research into drugs for diseases of the developing world, AstraZeneca CEO David Brennan suggested during a Nov. 10 press briefing at the 25 International Federation of Pharmaceutical Manufacturers & Associations Assembly in Washington, D.C